Dynamic facial expressions of emotions are discriminated at birth. DATASET

Dataset from the article: Addabbo M., Longhi E., Marchis I.C., Tagliabue P., Turati C. (2018). Dynamic facial expressions of emotions are discriminated at birth. PlosOne

Stimuli and results.

<p><b>a)</b> Frames composing the videos depicting the expression of disgust (left) and happiness (right) of one of the two face identities shown. Frames are presented in succession in the direction indicated by the arrow. The actress in the photograph has given written informed consent to publication of her photograph. <b>b)</b> Newborns’ total looking times (left) and orienting responses (right) towards the expression of happiness and disgust in Experiment 1 (Preference task). <b>c)</b> Newborns’ total looking times (left) and orienting responses (right) towards the novel and the familiar expression in the test phase of Experiment 2 (Habituation task). Error bars refer to the standard errors of the mean. * = p<.05.</p

Photophysics and Electrochemiluminescence of Bright Cyclometalated Ir(III) Complexes in Aqueous Solutions

A family of neutral bis-cyclometalated iridium complexes [Ir­(C^∧N)₂(LX)] has been investigated as ECL labels under immunoassay conditions. Among them, the complex based on phenylphenanthridine (pphent) as the C^∧N ligand, exhibits outstanding performance and it is a candidate to substitute the commercially available Ru-based label in diagnostics

Liikunnan positiiviset vaikutukset alle kouluikäisen lapsen kehitykseen : Terveysnetti

Liikunnalla on positiivisia vaikutuksia lapsen kaikkiin kehityksen osa-alueisiin. Liikkumisesta ja liikunnan harrastamisesta on hyötyä sekä lapsen fyysiselle että psyykkiselle kehitykselle. Liikunta toimii oivana tukijana lapsen motoristen, kognitiivisten ja sosiaalisten taitojen oppimisessa. Liikunnan kautta lapsi oppii tuntemaan niin itseään kuin ympäröivää maailmaakin. Vanhemmilla on merkittävä rooli lasten liikkumisessa. Vanhemmat näyttävät omalla käytöksellään mallia lapsille liikunnallisesta elämäntavasta. Heistä on myös kiinni lapsen päivittäisen ulkoilun ja liikkumisen määrä. Liikunnallisen elämäntavan omaksuminen jo lapsuudessa on tärkeä asia myös yksilön tulevaisuuden kannalta. Liikkuvasta lapsesta tulee todennäköisemmin myös liikkuva aikuinen. Opinnäytetyö toteutettiin projektina yhteistyössä Salon seudun terveyskeskuksen kanssa. Aineisto opinnäytetyöhön saatiin alan tutkimuksista ja tieteellisistä julkaisuista. Opinnäytetyön tehtävänä oli tuottaa verkkosivut Turun ammattikorkeakoulun Terveysnettiin liikunnan positiivisista vaikutuksista alle kouluikäisen lapsen kehitykseen. Tavoitteena on lisätä vanhempien tietoisuutta liikunnan hyvistä vaikutuksista lapsuudessa. Opinnäytetyöstä saatua tietoa voidaan hyödyntää liikunnanedistämistyössä. Projektin tuloksena syntyneet verkkosivut ovat nykyaikainen, yksinkertainen ja helppo tapa jakaa tietoa liikunnasta, jota perheet, terveydenhoitajat ja päiväkodit voivat hyödyntää omassa toiminnassaan.Exercise has positive effects on every area in child’s development. Physical activity is useful for both physical and psychological development. A child also needs exercise for learning motor, cognitive and social skills. Through physical activity a child can learn to know himself/herself and the world around. Parents have an important role in children’s exercise. Parents show their children an example how to live in a healthy and physically active way. It is also up to them how much a child is able to be outdoors and physically active daily. Learning to be physically active in the childhood is important thing for individual’s future too. Physically active child is likely to become a physically active adult. The project was made in co-operation with health care center of Salo area. The material for the thesis was collected from suitable researches and scientific publications. Purpose of the project was to produce Internet-sites about children’s physical activity to Terveysnetti, which is a website maintained by Turku University of Applied Sciences. The goal of the project was to increase parents’ knowledge about positive effects of exercise to children. The information is aimed especially to parents with children under school age and to different kind of professional groups which work with children, such as health care nurses and day care workers. Knowledge achieved from the project can be used in exercise promotion work. The results of the project, pages in the Internet, are modern, simple and easy way to share information about physical activity

image_5_Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy.tif

<p>We report here the long-term clinical and immunological results of four living-donor kidney transplant patients given autologous bone marrow-derived mesenchymal stromal cells (MSCs) as part of a phase 1 study focused on the safety and feasibility of this cell therapy. According to study protocols implemented over time, based on initial early safety findings, the patients were given MSC at day 7 posttransplant (n = 2) or at day −1 pretransplant (n = 2) and received induction therapy with basiliximab and low-dose rabbit anti-thymocyte globulin (RATG) or RATG alone, and were maintained on low-dose ciclosporin (CsA)/mycophenolate mofetil (MMF). All MSC-treated patients had stable graft function during the 5- to 7-year follow-up, without increased susceptibility to infections or neoplasm. In three MSC recipients, but not historical control patients, circulating memory CD8⁺ T cell percentages remained lower than basal, coupled with persistent reduction of ex vivo donor-specific cytotoxicity. Two patients showed a long-lasting increase in the regulatory T cell/memory CD8⁺ T cell ratio, paralleled by high circulating levels of naïve and transitional B cells. In one of these two patients, CsA was successfully discontinued, and currently the low-dose MMF monotherapy is on the tapering phase. The study shows that MSC therapy is safe in the long term and could promote a pro-tolerogenic environment in selected patients. Extensive immunomonitoring of MSC-treated kidney transplant recipients could help selection of patients for safe withdrawal of maintenance immunosuppressive drugs (NCT00752479 and NCT02012153).</p

image_4_Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy.tif

<p>We report here the long-term clinical and immunological results of four living-donor kidney transplant patients given autologous bone marrow-derived mesenchymal stromal cells (MSCs) as part of a phase 1 study focused on the safety and feasibility of this cell therapy. According to study protocols implemented over time, based on initial early safety findings, the patients were given MSC at day 7 posttransplant (n = 2) or at day −1 pretransplant (n = 2) and received induction therapy with basiliximab and low-dose rabbit anti-thymocyte globulin (RATG) or RATG alone, and were maintained on low-dose ciclosporin (CsA)/mycophenolate mofetil (MMF). All MSC-treated patients had stable graft function during the 5- to 7-year follow-up, without increased susceptibility to infections or neoplasm. In three MSC recipients, but not historical control patients, circulating memory CD8⁺ T cell percentages remained lower than basal, coupled with persistent reduction of ex vivo donor-specific cytotoxicity. Two patients showed a long-lasting increase in the regulatory T cell/memory CD8⁺ T cell ratio, paralleled by high circulating levels of naïve and transitional B cells. In one of these two patients, CsA was successfully discontinued, and currently the low-dose MMF monotherapy is on the tapering phase. The study shows that MSC therapy is safe in the long term and could promote a pro-tolerogenic environment in selected patients. Extensive immunomonitoring of MSC-treated kidney transplant recipients could help selection of patients for safe withdrawal of maintenance immunosuppressive drugs (NCT00752479 and NCT02012153).</p

table_1_Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy.PDF

<p>We report here the long-term clinical and immunological results of four living-donor kidney transplant patients given autologous bone marrow-derived mesenchymal stromal cells (MSCs) as part of a phase 1 study focused on the safety and feasibility of this cell therapy. According to study protocols implemented over time, based on initial early safety findings, the patients were given MSC at day 7 posttransplant (n = 2) or at day −1 pretransplant (n = 2) and received induction therapy with basiliximab and low-dose rabbit anti-thymocyte globulin (RATG) or RATG alone, and were maintained on low-dose ciclosporin (CsA)/mycophenolate mofetil (MMF). All MSC-treated patients had stable graft function during the 5- to 7-year follow-up, without increased susceptibility to infections or neoplasm. In three MSC recipients, but not historical control patients, circulating memory CD8⁺ T cell percentages remained lower than basal, coupled with persistent reduction of ex vivo donor-specific cytotoxicity. Two patients showed a long-lasting increase in the regulatory T cell/memory CD8⁺ T cell ratio, paralleled by high circulating levels of naïve and transitional B cells. In one of these two patients, CsA was successfully discontinued, and currently the low-dose MMF monotherapy is on the tapering phase. The study shows that MSC therapy is safe in the long term and could promote a pro-tolerogenic environment in selected patients. Extensive immunomonitoring of MSC-treated kidney transplant recipients could help selection of patients for safe withdrawal of maintenance immunosuppressive drugs (NCT00752479 and NCT02012153).</p

A Multitechnique Physicochemical Investigation of Various Factors Controlling the Photoaction Spectra and of Some Aspects of the Electron Transfer for a Series of Push–Pull Zn(II) Porphyrins Acting as Dyes in DSSCs

A multitechnique physicochemical comparative investigation involving TDDFT theoretical calculations, steady-state and time-resolved electronic absorption spectra, and electrochemical and photoelectrochemical investigations was carried out on a family of push–pull porphyrinic sensitizers ([5-(4′-carboxy-phenylethynyl)-15-(4″-methoxy-phenylethynyl)-10,20-bis(3,5-di-<i>tert</i>-butylphenyl)porphyrinate]Zn(II) (<b>1</b>) and [5-(4′-carboxy-phenylethynyl)-15-(4″-<i>N</i>,<i>N</i>-dimethylamino-phenylethynyl)-10,20-bis(3,5-di-<i>tert</i>-butylphenyl)porphyrinate]Zn(II) (<b>2</b>) and the new fluorinated porphyrinic dye [5-(4′-carboxy-2′,3′,5′,6′-tetrafluorophenylethynyl)-15-(4″-<i>N</i>,<i>N</i>-dimethylamino-phenylethynyl)-10,20-bis(3,5-di-<i>tert</i>-butylphenyl)porphyrinate]Zn(II) (<b>3</b>)) with the aim of identifying the structurally related electronic properties at the basis of efficient interfacial charge separation. We found for all dyes a photoconversion nearly twice more effective for the B band than for the Q band, which could not be explained only by considerations based on the electron collection efficiency but also by a more energetically favorable electron injection from the S2 excited state. The lower photoconversion of the fluorinated dye <b>3</b>, when compared to dyes <b>1</b> and <b>2</b>, was explained not only by a more difficult absorption on the TiO₂ photoanode but also by a lower electron injection efficiency and a less successful hole transfer to the electrolyte, leading to increased charge recombination

image_3_Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy.tif

<p>We report here the long-term clinical and immunological results of four living-donor kidney transplant patients given autologous bone marrow-derived mesenchymal stromal cells (MSCs) as part of a phase 1 study focused on the safety and feasibility of this cell therapy. According to study protocols implemented over time, based on initial early safety findings, the patients were given MSC at day 7 posttransplant (n = 2) or at day −1 pretransplant (n = 2) and received induction therapy with basiliximab and low-dose rabbit anti-thymocyte globulin (RATG) or RATG alone, and were maintained on low-dose ciclosporin (CsA)/mycophenolate mofetil (MMF). All MSC-treated patients had stable graft function during the 5- to 7-year follow-up, without increased susceptibility to infections or neoplasm. In three MSC recipients, but not historical control patients, circulating memory CD8⁺ T cell percentages remained lower than basal, coupled with persistent reduction of ex vivo donor-specific cytotoxicity. Two patients showed a long-lasting increase in the regulatory T cell/memory CD8⁺ T cell ratio, paralleled by high circulating levels of naïve and transitional B cells. In one of these two patients, CsA was successfully discontinued, and currently the low-dose MMF monotherapy is on the tapering phase. The study shows that MSC therapy is safe in the long term and could promote a pro-tolerogenic environment in selected patients. Extensive immunomonitoring of MSC-treated kidney transplant recipients could help selection of patients for safe withdrawal of maintenance immunosuppressive drugs (NCT00752479 and NCT02012153).</p

image_2_Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy.tif

<p>We report here the long-term clinical and immunological results of four living-donor kidney transplant patients given autologous bone marrow-derived mesenchymal stromal cells (MSCs) as part of a phase 1 study focused on the safety and feasibility of this cell therapy. According to study protocols implemented over time, based on initial early safety findings, the patients were given MSC at day 7 posttransplant (n = 2) or at day −1 pretransplant (n = 2) and received induction therapy with basiliximab and low-dose rabbit anti-thymocyte globulin (RATG) or RATG alone, and were maintained on low-dose ciclosporin (CsA)/mycophenolate mofetil (MMF). All MSC-treated patients had stable graft function during the 5- to 7-year follow-up, without increased susceptibility to infections or neoplasm. In three MSC recipients, but not historical control patients, circulating memory CD8⁺ T cell percentages remained lower than basal, coupled with persistent reduction of ex vivo donor-specific cytotoxicity. Two patients showed a long-lasting increase in the regulatory T cell/memory CD8⁺ T cell ratio, paralleled by high circulating levels of naïve and transitional B cells. In one of these two patients, CsA was successfully discontinued, and currently the low-dose MMF monotherapy is on the tapering phase. The study shows that MSC therapy is safe in the long term and could promote a pro-tolerogenic environment in selected patients. Extensive immunomonitoring of MSC-treated kidney transplant recipients could help selection of patients for safe withdrawal of maintenance immunosuppressive drugs (NCT00752479 and NCT02012153).</p